Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neuroscience Bulletin
Published in: Neuroscience Bulletin 5/2017

01-10-2017 | Review

Can Biomarkers Help the Early Diagnosis of Parkinson’s Disease?

Authors: Weidong Le, Jie Dong, Song Li, Amos D. Korczyn

Published in: Neuroscience Bulletin | Issue 5/2017

Login to get access

Abstract

Parkinson’s disease (PD) is a complex neurodegenerative disease with progressive loss of dopamine neurons. PD patients usually manifest a series of motor and non-motor symptoms. In order to provide better early diagnosis and subsequent disease-modifying therapies for PD patients, there is an urgent need to identify sensitive and specific biomarkers. Biomarkers can be divided into four categories: clinical, imaging, biochemical, and genetic. Ideal biomarkers not only improve our understanding of PD pathogenesis and progression, but also provide benefits for early risk evaluation and clinical diagnosis of PD. Although many efforts have been made and several biomarkers have been extensively investigated, few if any have been found useful for early diagnosis. Here, we summarize recent developments in the discovered biomarkers of PD and discuss their merits and limitations for the early diagnosis of PD.
Literature
1.
Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain 2013, 136: 2419–2431.CrossRefPubMedPubMedCentral
2.
Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord 2015, 30: 1600–1611.CrossRefPubMed
3.
Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson’s disease. Mov Disord 2014, 29: 454–462.CrossRefPubMedPubMedCentral
4.
Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L, Premi E, et al. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 2008, 71: 1796–1803.CrossRefPubMed
5.
Wu Y, Le W, Jankovic J. Preclinical biomarkers of Parkinson disease. Arch Neurol 2011, 68: 22–30.PubMed
6.
Rachakonda V, Pan TH, Le WD. Biomarkers of neurodegenerative disorders: how good are they? Cell Res 2004, 14: 347–358.CrossRefPubMed
7.
8.
Mandel SA, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy. EPMA J 2010, 1: 273–292.CrossRefPubMedPubMedCentral
9.
Berg D, Godau J, Seppi K, Behnke S, Liepelt-Scarfone I, Lerche S, et al. The PRIPS study: screening battery for subjects at risk for Parkinson’s disease. Eur J Neurol 2013, 20: 102–108.CrossRefPubMed
10.
Gaenslen A, Wurster I, Brockmann K, Huber H, Godau J, Faust B, et al. Prodromal features for Parkinson’s disease - baseline data from the TREND study. Eur J Neurol 2014, 21: 766–772.CrossRefPubMed
11.
Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, et al. Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study. Neurology 2014, 83: 1739–1746.CrossRefPubMedPubMedCentral
12.
Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study. Acta Neuropathol 2016, 131: 935–949.CrossRefPubMedPubMedCentral
13.
Chahine LM, Xie SX, Simuni T, Tran B, Postuma R, Amara A, et al. Longitudinal changes in cognition in early Parkinson’s disease patients with REM sleep behavior disorder. Parkinsonism Relat Disord 2016, 27: 102–106.CrossRefPubMedPubMedCentral
14.
Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Tanner C, Marek K, et al. How stable are Parkinson’s disease subtypes in de novo patients: Analysis of the PPMI cohort? Parkinsonism Relat Disord 2016, 28: 62–67.CrossRefPubMed
15.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Knowles CH, Hardy J, et al. PREDICT-PD: Identifying risk of Parkinson’s disease in the community: methods and baseline results. J Neurol Neurosurg Psychiatry 2014, 85: 31–37.CrossRefPubMed
16.
Noyce AJ, R’Bibo L, Peress L, Bestwick JP, Adams-Carr KL, Mencacci NE, et al. PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson’s disease. Mov Disord 2017, 32: 219–226.CrossRefPubMedPubMedCentral
17.
Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013, 12: 443–453.CrossRefPubMed
18.
Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY. How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain 2012, 135: 1860–1870.CrossRefPubMed
19.
Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 2015, 14: 57–64.CrossRefPubMed
20.
21.
Sixel-Döring F, Zimmermann J, Wegener A, Mollenhauer B, Trenkwalder C. The evolution of REM sleep behavior disorder in early Parkinson disease. Sleep 2016, 39: 1737–1742.CrossRefPubMedPubMedCentral
22.
Sixel-Döring F, Trautmann E, Mollenhauer B, Trenkwalder C. Rapid eye movement sleep behavioral events: a new marker for neurodegeneration in early Parkinson disease? Sleep 2014, 37: 431.CrossRefPubMedPubMedCentral
23.
Siderowf A, Jennings D, Eberly S, Oakes D, Hawkins KA, Ascherio A, et al. Impaired olfaction and other prodromal features in the Parkinson at-risk syndrome study. Mov Disord 2012, 27: 406–412.CrossRefPubMed
24.
Xiao Q, Chen S, Le W. Hyposmia: a possible biomarker of Parkinson’s disease. Neurosci Bull 2014, 30: 134–140.CrossRefPubMed
25.
Postuma RB, Berg D. Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 2016, 12: 622–634.CrossRefPubMed
26.
Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015, 84: 1104–1113.CrossRefPubMedPubMedCentral
27.
Ponsen MM, Stoffers D, Twisk JWR, Wolters EC, Berendse HW. Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: a prospective study. Mov Disord 2009, 24: 1060–1065.CrossRefPubMed
28.
Korczyn, AD. Autonomic nervous system disturbances in Parkinson’s disease. Adv Neurol 1990, 53: 463–468.PubMed
29.
Svensson E, Henderson VW, Borghammer P, Horváth-Puhó E, Sørensen HT. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study. Parkinsonism Relat Disord 2016, 28: 18–22.CrossRefPubMed
30.
Treves, TA, Chandra V, Korczyn AD. Parkinson’s and Alzheimer’s diseases: epidemiological comparison. 2. Persons at risk. Neuroepidemiology 1993, 12: 345–349.CrossRefPubMed
31.
Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology 2015, 84: 2422–2429.CrossRefPubMedPubMedCentral
32.
Suwijn SR, van Boheemen CJ, de Haan RJ, Tissingh G, Booij J, de Bie RM. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review. EJNMMI Res 2015, 5: 12.CrossRefPubMedPubMedCentral
33.
Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinson’s disease. Mov Disord 2012, 27: 1392–1397.CrossRefPubMedPubMedCentral
34.
Iranzo A, Lomeña F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010, 9: 1070–1077.CrossRefPubMed
35.
Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: It can be a specific marker for Lewy body disease. Ann Nucl Med 2004, 18: 453–461.CrossRefPubMed
36.
Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinsonism Relat Disord 2010, 16: 252–255.CrossRefPubMed
37.
Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 2006, 67: 2236–2238.CrossRefPubMed
38.
Lebasnier A, Lamotte G, Manrique A, Peyronnet D, Bouvard G, Defer G, et al. Potential diagnostic value of regional myocardial adrenergic imaging using (123)I-MIBG SPECT to identify patients with Lewy body diseases. Eur J Nucl Med Mol Imaging 2015, 42: 1043–1051.CrossRefPubMed
39.
Ellmore TM, Castriotta RJ, Hendley KL, Aalbers BM, Furr-Stimming E, Hood AJ, et al. Altered nigrostriatal and nigrocortical functional connectivity in rapid eye movement sleep behavior disorder. Sleep 2013, 36: 1885–1892.CrossRefPubMedPubMedCentral
40.
Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011, 69: 400–407.CrossRefPubMed
41.
He N, Ling H, Ding B, Huang J, Zhang Y, Zhang Z, et al. Region-specific disturbed iron distribution in early idiopathic Parkinson’s disease measured by quantitative susceptibility mapping. Hum Brain Mapp 2015, 36: 4407–4420.CrossRefPubMed
42.
Langley J, Huddleston DE, Merritt M, Chen X, McMurray R, Silver M, et al. Diffusion tensor imaging of the substantia nigra in Parkinson’s disease revisited. Hum Brain Mapp 2016, 37: 2547–2556.CrossRefPubMedPubMedCentral
43.
Langley J, Huddleston DE, Sedlacik J, Boelmans K, Hu XP. Parkinson’s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. Mov Disord 2017, 32: 441–449.CrossRefPubMed
44.
Jesus-Ribeiro J, Freire A, Sargento-Freitas J, Sousa M, Silva F, Moreira F, et al. Transcranial sonography and DaTSCAN in early stage Parkinson’s disease and essential tremor. Eur Neurol 2016, 76: 252–255.CrossRefPubMed
45.
Iranzo A, Stockner H, Serradell M, Seppi K, Valldeoriola F, Frauscher B, et al. Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2014, 29: 1774–1780.CrossRefPubMed
46.
Mollenhauer B. Quantification of α-synuclein in cerebrospinal fluid: how ideal is this biomarker for Parkinson’s disease? Parkinsonism Relat Disord 2014, 20: S76–S79.CrossRefPubMed
47.
Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, et al. Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease. Acta Neuropathol 2014, 128: 639–650.CrossRefPubMedPubMedCentral
48.
Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson’s disease. Brain 2015, 138: 2659–2671.CrossRefPubMedPubMedCentral
49.
Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 2010, 133: 713–726.CrossRefPubMedPubMedCentral
50.
Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 2012, 72: 893–901.CrossRefPubMedPubMedCentral
51.
de Lau LML, Koudstaal PJ, Hofman A, Breteler MMB. Serum uric acid levels and the risk of Parkinson disease. Ann Neurol 2005, 58: 797–800.CrossRefPubMed
52.
Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord 2015, 30: 1648–56.CrossRefPubMedPubMedCentral
53.
Qiang JK, Wong YC, Siderowf A, Hurtig HI, Xie SX, Lee VM, et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. Ann Neurol 2013, 74: 119–127.CrossRefPubMedPubMedCentral
54.
Santiago JA, Littlefield AM, Potashkin JA. Integrative transcriptomic meta-analysis of Parkinson’s disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson’s disease. Sci Rep 2016, 6: 34579.CrossRefPubMedPubMedCentral
55.
Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, Grosset DG. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson’s disease - a systematic review. Acta Neurol Scand 2014, 130: 59–72.CrossRefPubMed
56.
Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol 2016, 79: 940–949.CrossRefPubMed
57.
Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, et al. Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 2014, 127: 235–241.CrossRefPubMed
58.
Woulfe JM, Gray MT, Munoz G. Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015, 85: 834.CrossRefPubMed
59.
Chung SJ, Kim J, Lee HJ, Ryu H-S, Kim K, Lee JH, et al. Alpha-synuclein in gastric and colonic mucosa in Parkinson’s disease: Limited role as a biomarker. Mov Disord 2016, 31: 241–249.CrossRefPubMed
60.
Donadio V, Incensi A, Leta V, Giannoccaro MP, Scaglione C, Martinelli P, et al. Skin nerve -synuclein deposits: A biomarker for idiopathic Parkinson disease. Neurology 2014, 82: 1362–1369.CrossRefPubMed
61.
Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease. Acta Neuropathol 2017, 133: 535–545.CrossRefPubMedPubMedCentral
62.
Vilas D, Iranzo A, Tolosa E, Aldecoa I, Berenguer J, Vilaseca I, et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol 2016, 15: 708–718.CrossRefPubMed
63.
Adler CH, Dugger BN, Hentz JG, Hinni ML, Lott DG, Driver-Dunckley E, et al. Peripheral synucleinopathy in early Parkinson’s disease: submandibular gland needle biopsy findings. Mov Disord 2016, 31: 250–256.CrossRefPubMedPubMedCentral
64.
Heijtz RD, Wang S, Anuar F, Qian Y, Björkholm B, Samuelsson A, et al. Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci USA 2011, 108: 3047–3052.CrossRefPubMedCentral
65.
Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 2015, 30: 350–358.CrossRefPubMed
66.
Fernández-Santiago R, Iranzo A, Gaig C, Serradell M, Fernández M, Tolosa E, et al. MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder. Ann Neurol 2015, 77: 895–901.CrossRefPubMed
67.
Vallelunga A, Ragusa M, Di Mauro S, Iannitti T, Pilleri M, Biundo R, et al. Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and Multiple System Atrophy. Front Cell Neurosci 2014, 8: 156.CrossRefPubMedPubMedCentral
68.
Teixeira dos Santos MC, Bell R, da Costa AN. Recent developments in circulating biomarkers in Parkinson’s disease: the potential use of miRNAs in a clinical setting. Bioanalysis 2016, 8: 2497–518.CrossRefPubMed
69.
Thacker EL, Ascherio A. Familial aggregation of Parkinson’s disease: a meta-analysis. Mov Disord 2008, 23: 1174–1183.CrossRefPubMed
70.
Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet 2015, 31: 140–149.CrossRefPubMed
71.
Le W, Chen S, Jankovic J. Etiopathogenesis of Parkinson disease: A New Beginning? Neuroscientist 2009, 15: 28–35.CrossRef
72.
Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol 2015, 72: 201–208.CrossRefPubMedPubMedCentral
73.
Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, et al. The risk of Parkinson’s disease in type 1 Gaucher disease. J Inherit Metab Dis 2010, 33: 167–173.CrossRefPubMedPubMedCentral
74.
McNeill A, Duran R, Hughes DA, Mehta A, Schapira AH. A clinical and family history study of Parkinson’s disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry 2012, 83: 853–854.CrossRefPubMedPubMedCentral
75.
Bergareche A, Rodríguez-Oroz MC, Estanga A, Gorostidi A, López de Munain A, Castillo-Triviño T, et al. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson’s disease. Mov Disord 2016, 31: 335–43.CrossRefPubMed
76.
Le W, Pan T, Huang M, Xu P, Xie W, Zhu W, et al. Decreased NURR1 gene expression in patients with Parkinson’s disease. J Neurol Sci 2008, 273: 29–33.CrossRefPubMedPubMedCentral
77.
Guo Y, Le WD, Jankovic J, Yang HR, Xu HB, Xie WJ, et al. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord 2011, 26: 1729–1732.CrossRefPubMed
78.
79.
Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet 2014, 46: 989–993.CrossRefPubMedPubMedCentral
80.
Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, et al. Diagnosis of Parkinson’s disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015, 14: 1002–1009.CrossRefPubMedPubMedCentral
81.
Mahlknecht P, Gasperi A, Willeit P, Kiechl S, Stockner H, Willeit J, et al. Prodromal Parkinson’s disease as defined per MDS research criteria in the general elderly community. Mov Disord 2016, 31: 1405–1408.CrossRefPubMed
Metadata
Title
Can Biomarkers Help the Early Diagnosis of Parkinson’s Disease?
Authors
Weidong Le
Jie Dong
Song Li
Amos D. Korczyn
Publication date
01-10-2017
Publisher
Springer Singapore
Published in
Neuroscience Bulletin / Issue 5/2017
Print ISSN: 1673-7067
Electronic ISSN: 1995-8218
DOI
https://doi.org/10.1007/s12264-017-0174-6

Other articles of this Issue 5/2017

Neuroscience Bulletin 5/2017 Go to the issue

Review

Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson’s Disease

Original Article

Longitudinal Alterations of Local Spontaneous Brain Activity in Parkinson’s Disease

Review

Region-Specific Iron Measured by MRI as a Biomarker for Parkinson’s Disease

Editorial

Biomarker Discovery in Parkinson’s Disease: Present Challenges and Future Opportunities

Report

Genetic Analysis of FBXO2, FBXO6, FBXO12, and FBXO41 Variants in Han Chinese Patients with Sporadic Parkinson’s Disease

Review

Olfactory Dysfunction as an Early Biomarker in Parkinson’s Disease